NWQ Investment Management Company LLC boosted its position in shares of Allergan plc (NYSE:AGN) by 64.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 225,549 shares of the company’s stock after buying an additional 88,573 shares during the quarter. NWQ Investment Management Company LLC’s holdings in Allergan were worth $36,895,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BB&T Investment Services Inc. boosted its stake in Allergan by 1,308.2% during the third quarter. BB&T Investment Services Inc. now owns 690 shares of the company’s stock worth $139,000 after buying an additional 641 shares during the period. Avestar Capital LLC purchased a new position in Allergan during the fourth quarter worth $113,000. Focused Wealth Management Inc boosted its stake in Allergan by 4,444.4% during the fourth quarter. Focused Wealth Management Inc now owns 818 shares of the company’s stock worth $134,000 after buying an additional 800 shares during the period. Acropolis Investment Management LLC purchased a new position in Allergan during the fourth quarter worth $153,000. Finally, Zions Bancorporation boosted its stake in Allergan by 1,115.6% during the third quarter. Zions Bancorporation now owns 936 shares of the company’s stock worth $192,000 after buying an additional 859 shares during the period. 78.40% of the stock is owned by institutional investors.
Shares of Allergan plc (NYSE:AGN) opened at $158.41 on Tuesday. Allergan plc has a 52-week low of $142.81 and a 52-week high of $256.80. The firm has a market capitalization of $54,790.00, a price-to-earnings ratio of -13.21, a PEG ratio of 1.11 and a beta of 1.29. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.06 and a current ratio of 1.16.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 28th. Investors of record on Wednesday, February 28th will be issued a $0.72 dividend. This is an increase from Allergan’s previous quarterly dividend of $0.70. This represents a $2.88 annualized dividend and a dividend yield of 1.82%. The ex-dividend date of this dividend is Tuesday, February 27th. Allergan’s payout ratio is presently -24.02%.
Several research firms have commented on AGN. Leerink Swann lifted their price objective on shares of Allergan from $237.00 to $242.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Vetr lowered shares of Allergan from a “buy” rating to a “hold” rating and set a $180.97 price objective for the company. in a research note on Wednesday, January 10th. Argus lowered shares of Allergan from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $256.80 to $160.07 in a research note on Thursday, December 7th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $191.00 price objective on shares of Allergan in a research note on Tuesday, February 6th. Finally, Morgan Stanley raised shares of Allergan from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $171.92 to $200.00 in a research note on Wednesday, November 29th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $225.03.
In other news, Director Joseph H. Boccuzi acquired 900 shares of the firm’s stock in a transaction that occurred on Monday, March 5th. The stock was purchased at an average cost of $143.42 per share, for a total transaction of $129,078.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider William Meury sold 58,879 shares of Allergan stock in a transaction dated Wednesday, February 14th. The shares were sold at an average price of $160.62, for a total value of $9,457,144.98. The disclosure for this sale can be found here. Insiders purchased 7,200 shares of company stock valued at $1,108,267 over the last 90 days. 0.36% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “Allergan plc (AGN) Holdings Lifted by NWQ Investment Management Company LLC” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://sportsperspectives.com/2018/03/13/allergan-plc-agn-holdings-lifted-by-nwq-investment-management-company-llc.html.
Allergan Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.